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B R I E F R E P O R T
Prophylaxis Failure Is
Associated with a Specific
Pneumocystis carinii Genotype
Philippe M. Hauser, Philippe Sudre, Aimable Nahimana,
Patrick Francioli, and the Study Groupa
Division Autonome de Me´decine Pre´ventive Hospitalie`re, Centre Hospitalier
Universitaire Vaudois, Lausanne, Switzerland
To investigate the possible association between Pneumocystis
carinii types and various clinical and demographic param-
eters, we used molecular typing to analyze 93 bronchoalveo-
lar lavage specimens from patients with P. carinii pneumonia
(PCP). Multivariate regression analysis revealed an associa-
tion between being infected with a specific P. carinii genotype
and receiving anti-PCP prophylaxis (odds ratio, 4.4; 95%
confidence interval, 1.0–18.6; ), although no associ-Pp .05
ation with a specific drug was detected.
Pneumocystis carinii pneumonia (PCP) is an important op-
portunistic infection among immunocompromised patients. In
the absence of a reliable method for in vitro culture of the
infecting organism, many aspects of PCP are poorly under-
stood. Cotrimoxazole is the first-line drug for prophylaxis and
treatment. Recently, nonsynonymous mutations in the P. carinii
gene encoding the target of this drug, dihydropteroate synthase,
were shown to be associated with failure of cotrimoxazole treat-
ment [1] and an increased mortality rate [2]. It has been sug-
gested that mutations altering the active site of cytochrome b,
which is the target of atovaquone, a second-line drug, also
confer resistance [3]. The isolation of mouse-derived strains of
P. carinii that do not respond to cotrimoxazole and that lack
alterations at the active site of dihydropteroate synthase suggests
that other resistance mechanisms, such as altered drug uptake
or detoxification, may also exist [4].
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We recently developed a molecular typing method for strains
of P. carinii that infect humans; this method consists of am-
plification of 4 variable regions of the genome, followed by
detection of polymorphisms by the single-strand conformation
polymorphism technique (SSCP) [5, 6]. This method was used
to investigate the possible association between P. carinii gen-
otypes and various clinical and demographic parameters of
infected patients. The results show that failure of primary or
secondary anti-PCP prophylaxis is associated with a specific P.
carinii genotype; this suggests that drug resistance may be de-
tected by molecular typing with the use of markers that are
unrelated to resistance.
Ninety-three bronchoalveolar lavage (BAL) specimens were
obtained from 91 patients with PCP who were admitted to 11
hospitals in European countries, as follows: Belgium (Brussels,
1 patient), Denmark (Copenhagen, 8), France (Lyon, 10; Paris,
9), Germany (Mu¨nster, 3), and Switzerland (Geneva, 4; La
Chaux-de-Fonds, 1; Lausanne, 21; Lugano, 5; St.-Gallen, 1;
Zurich, 28). The specimens were selected for study because
data were available on the following variables: the patient’s sex,
age, HIV status, number of PCP episodes, CD4 count, anti-
PCP prophylaxis regimen, and geographical origin, and the
infecting P. carinii genotype. P. carinii organisms were typed
using the PCR-SSCP method, as described elsewhere [5, 6].
The possible association between P. carinii genotypes and var-
ious clinical and demographic parameters was analyzed with
SPSS 8.0 statistical software (SPSS). An association was con-
sidered to be statistically significant if (x2 test forP .05
proportion).
The 91 patients ranged in age from 23 to 82 years (median,
35 years), and most (75%) were men. The majority of the 93
specimens (85%) were from AIDS patients. Eighty-one of the
specimens were from patients with their first episode of PCP,
11 were from patients with their second episode, and 1 was
from a patient with a third episode. Sixty-three episodes of PCP
occurred in patients who had not received PCP prophylaxis,
and 30 episodes occurred in patients receiving prophylaxis with
the following drugs: aerosolized pentamidine (14 patients), co-
trimoxazole (8), dapsone (4), atovaquone (1), and an unde-
termined drug (3). Of the 30 patients receiving prophylaxis, 4
did not comply with their drug regimen during the month
before PCP was diagnosed.
Twenty-eight different P. carinii types were identified by use
of the PCR-SSCP method. Forty-three specimens contained a
single P. carinii type, 49 specimens contained 2 types, and 1
specimen contained 3 types. The same types were identified in
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Table 1. Multivariate analysis of risk factors for infection with
Pneumocystis carinii type 6 among 91 patients with P. carinii
pneumonia.
Risk factor
No. (%)
of patients,
by infecting
P. carinii genotype
Adjusted OR
(95% CI)a PType 6 Other
Received prophylaxis .05
Yes 9 (69) 21 (26) 4.4 (1.0–18.6)
No 4 (31) 59 (74) Reference
Period specimen was
collected
.56
1989–1994 5 (39) 26 (32) 1.3 (0.3–6.5)
1995–1996 7 (54) 35 (44) Reference
1997–1998 1 (7) 19 (24) 0.4 (0.0–3.9)
CD4 count, cells/mm3 .46
Unknown 3 (23) 31 (39) 1.0 (0.1–11.9)
0–24 7 (54) 22 (27) 3.2 (0.3–34.8)
25–49 2 (15) 11 (14) 2.7 (0.2–40.4)
50–160 1 (8) 16 (20) Reference
Coinfection with 11 type
of P. carinii
.26
Yes 3 (23) 47 (59) 0.4 (0.1–1.9)
No 10 (77) 33 (41) Reference
NOTE. a OR for infection with P. carinii type 6 after adjustment for the 4
variables presented in the table.
specimens obtained at different hospitals several years apart.
The 2 patients with 2 episodes of PCP were infected with dif-
ferent types at each episode.
Univariate comparison revealed that there was a significant
association between being infected with P. carinii type 6 and
receiving anti-PCP prophylaxis ( ). None of the otherPp .02
genotypes was associated with this or other characteristics.
Multivariate regression analysis, which included data on the
year the specimen was collected, the patient’s CD4 count, and
the occurrence of coinfection, confirmed that there was an
independent association between being infected with P. carinii
type 6 and receiving anti-PCP prophylaxis (OR, 4.4; 95% CI,
1.0–18.6; ; table 1). No association with a specific drugPp .05
was detected. Infection with P. carinii type 6 occurred in pa-
tients receiving prophylaxis with pentamidine (5 patients), dap-
sone (3), and atovaquone (1). Seven of the 9 patients were
compliant with prophylaxis during the month before PCP was
diagnosed; compliance information was not available for 2 pa-
tients. The outcome of PCP episodes that involved P. carinii
type 6 did not suggest drug resistance when therapeutic doses
of anti-PCP drugs were used. The gene coding for dihydrop-
teroate synthase of 3 isolates of P. carinii type 6 was amplified,
sequenced, and compared with that of the wild-type allele
(GenBank accession number U66283). No mutation was found
(results not shown).
Among the 93 PCP episodes, we observed a broad diversity
of infecting genotypes and a high frequency of coinfection. The
stability of the genotypes that were found and their ubiqui-
tousness were suggested by the observation of the same types
in specimens obtained at different hospitals several years apart.
These findings are in agreement with those of our previous
studies [5–7].
The present study found an association between being in-
fected with P. carinii type 6 and receiving anti-PCP prophylaxis.
Being infected with type 6, rather than noncompliance with
prophylaxis, seems to be associated with prophylaxis failure.
Although the small numbers of patients limited the power of
the study, the association between infection with type 6 and
receiving prophylaxis was apparently independent of the drug
received. Thus, a mechanism that confers multiple resistance
may be present in P. carinii type 6. However, it is also possible
that this genotype is more prone to accumulate mutations than
are other types and thus is more likely to acquire drug resistance
under selective pressure. Selection of resistant clones may have
occurred in patients receiving prophylaxis; or it may have oc-
curred in a limited number of patients, followed by dissemi-
nation of resistant clones. The fact that PCP episodes due to
P. carinii type 6 responded favorably to treatment could be due
to the higher doses of drugs given for treatment compared with
the doses given for prophylaxis.
The findings of the present study are consistent with those
of another study [10]. Indeed, the PCR-SSCP method assigned
type 6 to P. carinii type B2a1 or type Ne, as defined by sequencing
of the internal transcribed spacers of the nuclear rRNA operon
[8, 9]. Type B2a1 has been reported to be associated with mild
pneumonia and to occur most frequently in patients with re-
current episodes of PCP [10]. Both observations may be due
to the drug resistance of this genotype. The mild severity could
reflect reduced virulence that is due to the acquisition of re-
sistance. The high frequency of type B2a1 in patients with re-
current episodes of PCP may have resulted from secondary
prophylaxis.
Our results suggest that failure of primary or secondary anti-
PCP prophylaxis is associated with a specific P. carinii genotype.
Thus, typing with use of the rapid PCR-SSCP method may
help predict resistance in a clinical situation and help improve
treatment. Further study of P. carinii type 6 detected by PCR-
SSCP may contribute to a better understanding of P. carinii
drug resistance.
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